Solubility-enhancing Excipient for Injectable Drug Formulations Wins Prestigious CPhI Barcelona Award

Lubrizol Life Science Health, a leading pharmaceutical company, has won the Finished Formulation Award at CPhI Barcelona for its innovative technology – Apisolex™ Polymer solubilizing excipient. With over 180 entries covering 12 innovation categories featuring many of pharma’s biggest names, Apisolex Polymer was again recognized as a breakthrough innovation adding to the prestigious award recognized by The Medicine Maker earlier this year. The winners were announced at a networking reception held at CPhI Barcelona with over 500 guests in attendance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231024985629/en/

Kevin Song, Ph.D., Global Marketing Director accepts CPhI Award for Apisolex™ Polymer on behalf of The Lubrizol Corporation. (Photo: Business Wire)

Apisolex™ Polymer is the first solubility-enhancing excipient to be launched specifically for parenteral use in over 20 years. Comprised of building blocks naturally occurring in the body, Apisolex™ is a poly(amino acid)--based excipient that provides drug formulators with the necessary tools and methods to enhance the solubility of hydrophobic APIs by up to 50,000-fold.

Approximately 60% of new chemical entities (NCEs) under development, and more than 40% of Active Pharmaceutical Ingredients (APIs) in reformulation are poorly water-soluble with each requiring tailored solutions. With several solubilizing excipients on the market, it is impossible to find a one-size-fits-all solution. Filling a crucial gap in the market, Apisolex™ Polymer enables novel brick-dust and grease ball APIs to be formulated, as well as providing existing APIs with the option to be repurposed or reformulated via the FDA’s 505(b)(2) regulatory pathway.

“By drawing on our 40+ year legacy, Lubrizol Life Science Health has developed a non-immunogenic, biocompatible, and biodegradable alternative to PEG-based excipients. Apisolex™ Polymer offers oncology, CNS, and high-value orphan drug formulators the tools necessary to unlock the potential of previously hard-to-formulate APIs, providing patients with access to life-changing therapeutics that otherwise may not have made it to market.” - Gaurab Sengupta, Senior Global Business Director, Pharmaceuticals & Nutraceuticals, Lubrizol Life Science Health.

Request a sample or speak with a solubility enhancement expert today.

About Lubrizol

The Lubrizol Corporation, a Berkshire Hathaway company, is a specialty chemical company whose science delivers sustainable solutions to advance mobility, improve wellbeing and enhance modern life. Founded in 1928, Lubrizol owns and operates more than 100 manufacturing facilities, sales and technical offices around the world and has more than 8,000 employees. For more information, visit www.Lubrizol.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231024985629/en/

Gabe Ellis
Global Marketing Communications Manager – Pharma
Gabe.ellis@lubrizol.com

Logo

Images

Tags

More Like This

Lubrizol Launches Carbopol® Polymers for Nutraceuticals with New EU Food Grade Approval

Lubrizol Showcases LIPOFER™ Microencapsulation Technology, Introduces New EU Food-Grade Approval for Carbopol® Polymers at Vitafoods Europe 2024

Americhem Launches New EcoLube™ Line of PFAS-Free Internally Lubricated Compounds

Kexing Biopharm made its appearance at CPHI Milan 2024: Launch Ceremony for Apexelsin® in EU market Successfully done

Olon Continues its Growth Path and Announces a New Acquisition

Kexing Biopharm's Albumin-bound Paclitaxel Granted EU Market Approval

Lubrizol Expands Collaboration with Oil Store to Grow Finished Fluids Business in the U.K., Europe, Middle East and North Africa

Cambrex Announces New Liquid-Phase Peptide Synthesis Manufacturing Technology